Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia
© 2022. The Author(s)..
All types of dementia, including Alzheimer's disease, are debilitating neurodegenerative conditions marked by compromised cognitive function for which there are few effective treatments. Positive modulation of hepatocyte growth factor (HGF)/MET, a critical neurotrophic signaling system, may promote neuronal health and function, thereby addressing neurodegeneration in dementia. Here, we evaluate a series of novel small molecules for their ability to (1) positively modulate HGF/MET activity, (2) induce neurotrophic changes and protect against neurotoxic insults in primary neuron culture, (3) promote anti-inflammatory effects in vitro and in vivo, and (4) reverse cognitive deficits in animal models of dementia. Through screening studies, the compound now known as fosgonimeton-active metabolite (fosgo-AM) was identified by use of immunocytochemistry to be the most potent positive modulator of HGF/MET and was selected for further testing. Primary hippocampal neurons treated with fosgo-AM showed enhanced synaptogenesis and neurite outgrowth, supporting the neurotrophic effects of positive modulators of HGF/MET. Additionally, fosgo-AM protected against neurotoxic insults in primary cortical neuron cultures. In vivo, treatment with fosgo-AM rescued cognitive deficits in the rat scopolamine amnesia model of dementia. Although fosgo-AM demonstrated several procognitive effects in vitro and in vivo, a prodrug strategy was used to enhance the pharmacological properties of fosgo-AM, resulting in the development of fosgonimeton (ATH-1017). The effect of fosgonimeton on cognition was confirmed in a lipopolysaccharide (LPS)-induced neuroinflammatory mouse model of dementia. Together, the results of these studies support the potential of positive modulators of HGF/MET to be used as novel therapeutics and suggest the drug candidate fosgonimeton might protect against neurodegeneration and be therapeutic in the management of Alzheimer's disease and other types of dementia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 20(2023), 2 vom: 08. März, Seite 431-451 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Johnston, Jewel L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
67256-21-7 |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 04.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s13311-022-01325-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350498520 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350498520 | ||
| 003 | DE-627 | ||
| 005 | 20240204231923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13311-022-01325-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1280.xml |
| 035 | |a (DE-627)NLM350498520 | ||
| 035 | |a (NLM)36538176 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Johnston, Jewel L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 04.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a All types of dementia, including Alzheimer's disease, are debilitating neurodegenerative conditions marked by compromised cognitive function for which there are few effective treatments. Positive modulation of hepatocyte growth factor (HGF)/MET, a critical neurotrophic signaling system, may promote neuronal health and function, thereby addressing neurodegeneration in dementia. Here, we evaluate a series of novel small molecules for their ability to (1) positively modulate HGF/MET activity, (2) induce neurotrophic changes and protect against neurotoxic insults in primary neuron culture, (3) promote anti-inflammatory effects in vitro and in vivo, and (4) reverse cognitive deficits in animal models of dementia. Through screening studies, the compound now known as fosgonimeton-active metabolite (fosgo-AM) was identified by use of immunocytochemistry to be the most potent positive modulator of HGF/MET and was selected for further testing. Primary hippocampal neurons treated with fosgo-AM showed enhanced synaptogenesis and neurite outgrowth, supporting the neurotrophic effects of positive modulators of HGF/MET. Additionally, fosgo-AM protected against neurotoxic insults in primary cortical neuron cultures. In vivo, treatment with fosgo-AM rescued cognitive deficits in the rat scopolamine amnesia model of dementia. Although fosgo-AM demonstrated several procognitive effects in vitro and in vivo, a prodrug strategy was used to enhance the pharmacological properties of fosgo-AM, resulting in the development of fosgonimeton (ATH-1017). The effect of fosgonimeton on cognition was confirmed in a lipopolysaccharide (LPS)-induced neuroinflammatory mouse model of dementia. Together, the results of these studies support the potential of positive modulators of HGF/MET to be used as novel therapeutics and suggest the drug candidate fosgonimeton might protect against neurodegeneration and be therapeutic in the management of Alzheimer's disease and other types of dementia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ATH-1017 | |
| 650 | 4 | |a Alzheimer’s dementia | |
| 650 | 4 | |a Fosgonimeton | |
| 650 | 4 | |a Hepatocyte growth factor (HGF) | |
| 650 | 4 | |a Neurodegeneration | |
| 650 | 4 | |a Neurotrophic factor | |
| 650 | 7 | |a Hepatocyte Growth Factor |2 NLM | |
| 650 | 7 | |a 67256-21-7 |2 NLM | |
| 700 | 1 | |a Reda, Sherif M |e verfasserin |4 aut | |
| 700 | 1 | |a Setti, Sharay E |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Robert W |e verfasserin |4 aut | |
| 700 | 1 | |a Berthiaume, Andrée-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, William E |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Moebius, Hans J |e verfasserin |4 aut | |
| 700 | 1 | |a Church, Kevin J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |d 2007 |g 20(2023), 2 vom: 08. März, Seite 431-451 |w (DE-627)NLM167471872 |x 1878-7479 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:2 |g day:08 |g month:03 |g pages:431-451 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13311-022-01325-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 2 |b 08 |c 03 |h 431-451 | ||